Huperzine aggravated neurochemical and volumetric changes induced by D-galactose in the model of neurodegeneration in rats.

The multimodal MRI and 1H MRS study was designed to provide a structural and neurochemical view of D-galactose induced rat brain degeneration and its treatment with huperzine A. The volume changes were captured using MRI focused on the hippocampal region and a neurochemical profile was obtained from the same area using in vivo localized 1H MRS, which was compared with in vitro1H MRS hippocampal spectra at the high field after the animals were culled. At the four week point, we observed a small decrease in N-acetylaspartate/creatine (NAA/tCr), myo-inositol/creatine (mIns/tCr) and glutamine/creatine (Gln/tCr) in the group in which neurodegeneration was induced. At the eight week point, we found only slight but statistically significant decreases in NAA/tCr, mIns/tCr and glutamate/creatine (Glu/tCr) in this group in vivo. However, in the treated group, the decrease in NAA/tCr and Glu/tCr was much more pronounced compared to the D-gal group. In vitro1H MRS analysis from rat hippocampal samples showed very similar changes in metabolites, which were also much more pronounced in the treated group. Neurodegeneration was also confirmed by a significant decrease in γ-aminobutyrate/creatine (GABA/tCr) observed only in the treated group, but not in the D-gal group. MRI image data and subsequent volumetric quantification showed mild hippocampal degeneration at the four week point in D-gal group. At the eight week point, we observed a decrease in hippocampal volume in both experimental groups, with a more pronounced decrease in the huperzine-treated group. In conclusion, in our experimental design huperzine A treatment worsened the neurodegeneration of the rat brain, which was supported by all of the used MRI and 1H MRS methods.

The plasma carnitine concentration regulates renal OCTN2 expression and carnitine transport in rats.

Previous findings in rats and in human vegetarians suggest that the plasma carnitine concentration and/or carnitine ingestion may influence the renal reabsorption of carnitine. We tested this hypothesis in rats with secondary carnitine deficiency following treatment with N-trimethyl-hydrazine-3-propionate (THP) for 2 weeks and rats treated with excess L-carnitine for 2 weeks. Compared to untreated control rats, treatment with THP was associated with an approximately 70% decrease in plasma carnitine and with a 74% decrease in the skeletal muscle carnitine content. In contrast, treatment with L-carnitine increased plasma carnitine levels by 80% and the skeletal muscle carnitine content by 50%. Treatment with L-carnitine affected neither the activity of carnitine transport into isolated renal brush border membrane vesicles, nor renal mRNA expression of the carnitine transporter OCTN2. In contrast, in carnitine deficient rats, carnitine transport into isolated brush border membrane vesicles was increased 1.9-fold compared to untreated control rats. Similarly, renal mRNA expression of OCTN2 increased by a factor of 1.7 in carnitine deficient rats, whereas OCTN2 mRNA expression remained unchanged in gut, liver or skeletal muscle. Our study supports the hypothesis that a decrease in the carnitine plasma and/or glomerular filtrate concentration increases renal expression and activity of OCTN2.